onr:"swepub:oai:DiVA.org:uu-352681"
Search: onr:"swepub:oai:DiVA.org:uu-352681" > Rapidly increasing ...
- 1 of 1
- Previous record
- Next record
- To hitlist
Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden : Outlier or predecessor?
-
- Berntsson, Shala G., 1964- (author)
- Uppsala universitet,Neurologi,Uppsala Univ, Sweden
-
- Kristoffersson, A (author)
- Uppsala universitet,Neurologi,Neurology Policlinic, Department of Medical Specialist, Motala General Hospital, Motala, Sweden,Uppsala Univ, Sweden; Motala Gen Hosp, Sweden
-
- Boström, Inger (author)
- Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping
- show more...
- show less...
- (creator_code:org_t)
- 2018-05-24
- 2018
- English.
- In: Acta Neurologica Scandinavica. - : Hindawi Limited. - 0001-6314 .- 1600-0404. ; 138:4, s. 327-331
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- OBJECTIVES: Off-label use of rituximab to treat MS patients in Sweden is high, and the need for long-term safety data may not be met. Our objectives were to assess the rate of rituximab prescription in patients with multiple sclerosis in Sweden and, in addition, to evaluate the safety of rituximab in a single centre for patients with multiple sclerosis.MATERIAL AND METHODS: Review of the Swedish MS register was performed to study the number of MS patients treated with rituximab during the last 6 years. Investigation also included a retrospective review of medical files in search for possible side effects/adverse events in all adult patients with MS treated with rituximab at Uppsala University Hospital.RESULTS: Presently, in Sweden the rate of rituximab prescriptions in relation to other annually started of disease- modifying drugs in MS is 53.5%.CONCLUSIONS: The share of MS patients in Sweden who are treated with rituximab is very high, and also rapidly increasing. Taken into account the off-label use, cases with adverse medical conditions that could possibly be related to rituximab use should be reported thoroughly.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Keyword
- adverse events
- immunomodulatory drugs
- multiple sclerosis
- off-label prescription
- pharmacotherapy
- rituximab side effects
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Acta Neurologica Scandinavica (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Berntsson, Shala ...
- Kristoffersson, ...
- Boström, Inger
- Feresiadou, Amal ...
- Burman, Joachim, ...
- Landtblom, Anne- ...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Neurology
- Articles in the publication
- Acta Neurologica ...
- By the university
- Uppsala University
- Linköping University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
